Teva Pharmaceuticals
TEVA
430 hedge funds and large institutions have $4.47B invested in Teva Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 44 funds opening new positions, 134 increasing their positions, 141 reducing their positions, and 64 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 6 → 12 (+6)
19% more capital invested
Capital invested by funds: $3.76B → $4.47B (+$709M)
4.85% more ownership
Funds ownership: 45.62% → 50.47% (+4.9%)
3% less call options, than puts
Call options by funds: $305M | Put options by funds: $314M
5% less repeat investments, than reductions
Existing positions increased: 134 | Existing positions reduced: 141
6% less funds holding
Funds holding: 456 → 430 (-26)
31% less first-time investments, than exits
New positions opened: 44 | Existing positions closed: 64
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
+$348M |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
+$212M |
| 3 |
LIM
Lingotto Investment Management
London,
United Kingdom
|
+$102M |
| 4 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$42M |
| 5 |
Two Sigma Investments
New York
|
+$40.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$75.7M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$63M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$58.8M |
| 4 |
Citigroup
New York
|
-$30.7M |
| 5 |
GAM
Goldentree Asset Management
New York
|
-$28.7M |
TEVA Hedge Fund Activity: Q3 2022 in Review
430 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Teva Pharmaceuticals (TEVA) for Q3 2022, worth a combined $4.47B — up 19% from $3.76B a quarter earlier.
Sellers outnumbered buyers: 64 funds closed out of TEVA and 44 opened new positions — a net loss of 20 holders — while 141 trimmed existing stakes and 134 added.
The largest buyer was Capital World Investors, opening a new position worth an estimated $348M. The largest seller was Millennium Management, cutting an estimated $75.7M.
- 430 institutional investors held Teva Pharmaceuticals (TEVA) as of Q3 2022, down from 456 in Q2 2022.
- Funds reported $4.47B of Teva Pharmaceuticals stock for Q3 2022, up 19% quarter-over-quarter.
- 44 funds opened new Teva Pharmaceuticals positions in Q3 2022 and 64 closed out, a net change of -20 holders.
- The largest Teva Pharmaceuticals buyer in Q3 2022 was Capital World Investors, an estimated $348M added.
- The largest Teva Pharmaceuticals seller in Q3 2022 was Millennium Management, an estimated $75.7M sold.
Based on aggregated 13F filings for Q3 2022.